AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

Completed · Phase 3 · Has a placebo group

Conditions studied: MRSA, Cystic Fibrosis

In brief

This is a multi-center, randomized phase III study to evaluate the clinical effectiveness of AeroVanc in persistent methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis (CF).

Key facts

Study ID

NCT03181932

Run by

Savara Inc.

People needed

188

Starts

2017-09-20

Expected to finish

2021-01-15

Last updated by the study team

2022-12-16

Who can join

Age: 6 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants ≥6 years of age at time of informed consent form or assent form signing.
• Confirmed diagnosis of CF, determined by having clinical features consistent with the CF phenotype, plus one of the following:
• Positive sweat chloride test (value ≥60 milliequivalent/L),
• Genotype with 2 mutations consistent with CF (i.e., a mutation in each of the cystic fibrosis transmembrane conductance regulator genes).
• Positive sputum culture or a throat swab culture for MRSA at Screening.
• In addition to the Screening sample, have at least 2 prior sputum or throat swab cultures positive for MRSA, of which at least 1 sample is >6 months prior to Screening. At least 50% of all MRSA cultures (sputum or throat swab culture) collected from the time of the first positive culture (in the previous 1 year) must have tested positive for MRSA. (Note: Screening sample may count towards 50% positive count)
• FEV1 ≥30% and ≤90% of predicted that is normal for age, gender, race, and height, using the Global Lung Function Initiative equation.
• At least 1 episode of acute pulmonary infection treated with non-maintenance antibiotics within 12 months prior to the Baseline visit (initiation of treatment with intermittent inhaled anti-Pseudomonal therapy will not qualify as treatment with non-maintenance antibiotics).
• If female of childbearing potential, an acceptable method of contraception must be used during the study and must be combined with a negative pregnancy test obtained during Screening; sexually active male subjects of reproductive potential who are non-sterile (i.e., male who has not been sterilized by vasectomy for at least 6 months, and were not diagnosed with infertility through demonstration of azoospermia in a semen sample and/or absence of vas deferens through ultrasound) must be willing to use a barrier method of contraception, or their female partner must use an acceptable method of contraception, during the study.
• For purposes of this study, the Sponsor defines "acceptable methods of contraception" as:
• Oral birth control pills administered for at least 1 monthly cycle prior to administration of the study drug.
• A synthetic progestin implanted rod (eg, Implanon®) for at least 1 monthly cycle prior to the study drug administration but not beyond the 4th successive year following insertion.
• Intrauterine devices, inserted by a qualified clinician for at least 1 monthly cycle prior to study drug administration.
• Medroxyprogesterone acetate (eg, Depo-Provera®) administered for a minimum of 1 monthly cycle prior to administration of the study drug and continuing through 1 month following study completion.
• Hysterectomy or surgical sterilization.
• Abstinence.
• Double barrier method (diaphragm with spermicidal gel or condoms with contraceptive foam).
• Note: For subjects prescribed Orkambi: Orkambi may substantially decrease hormonal contraceptive exposure, reducing the effectiveness and increasing the incidence of menstruation-associated adverse reactions. Hormonal contraceptives, including oral, injectable, transdermal, and implantable, should not be relied upon as an effective method of contraception when co-administered with Orkambi.
• Able and willing to comply with the protocol, including availability for all scheduled study visits and able to perform all techniques necessary to use the AeroVanc inhaler and measure lung function.
• Agree not to smoke during any part of the clinical trial (Screening visit through end of study).
• Participants with a Pseudomonas aeruginosa co-infection must either be stable on a regular suppression regimen of inhaled antibiotics or must be, in the opinion of the Investigator, stable despite the lack of such treatment.

You may not qualify if…

• Use of anti-MRSA treatments prescribed as maintenance therapy (intravenous [IV] or inhaled treatment within 28 days; oral treatment within 14 days) prior to the Baseline visit.
• Use of non-maintenance antibiotic for pulmonary infection or extrapulmonary MRSA infection (IV or inhaled antibiotic within 28 days; oral antibiotic within 14 days) prior to the Baseline visit.
• History of previous allergies or sensitivity to vancomycin, or other component(s) of the study drug or placebo except for a history of red-man syndrome.
• Inability to tolerate inhaled products.
• First time sputum culture or throat swab culture yielding Burkholderia cepacia, or nontuberculous Mycobacteria in the previous 6 months to Screening.
• History of lung or other solid organ transplantation or currently on the list to receive lung or other solid organ transplantation.
• Resistance to vancomycin at Screening (vancomycin resistant Staphylococcus aureus, or vancomycin intermediate resistant Staphylococcus aureus, with minimum inhibitory concentration ≥8 μg/mL).
• Oral corticosteroids in doses exceeding 10 mg prednisone per day or 20 mg prednisone every other day, or equipotent doses of other corticosteroids.
• Changes in antimicrobial, bronchodilator, anti-inflammatory or corticosteroid medications within 14 days, or changes in cystic fibrosis transmembrane conductance modulators within 28 days, prior to the Baseline visit.
• Abnormal laboratory findings or other findings or medical history at Screening that, in the Investigator's opinion, would compromise the safety of the subject or the quality of the study data.
• Inability to tolerate inhalation of a short acting beta2 agonist
• Oxygen saturation <90% at Screening.
• Changes in physiotherapy technique or physiotherapy scheduled within 1 week of the Baseline visit.
• Administration of any investigational drug or device within 4 weeks prior to the Screening visit and during the study
• Female with positive pregnancy test result during Screening, pregnant (or intends to become pregnant), lactating or intends to breastfeed during the study.
• Renal insufficiency, defined as creatinine clearance <50 mL/min using the Cockcroft-Gault equation for adults or Schwartz equation for children at the Screening visit.
• Abnormal liver function, defined as ≥4x upper limit of normal of serum aspartate aminotransferase or serum alanine aminotransferase, or known cirrhosis at Screening.
• Diagnosed with clinically significant hearing loss.
• History of positive result for human immunodeficiency virus, hepatitis B virus or hepatitis C virus.
• Planned hospitalizations for prophylaxis antibiotic treatment within 28 days prior to Baseline visit or during the double-blind period (Period 1).

Where it is running

• Phoenix Children's Hospital — Phoenix, Arizona, United States
• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States
• Miller Childrens Hospital MemorialCare Health System Pediatric Pulmonology — Long Beach, California, United States
• Children's Hospital Los Angeles — Los Angeles, California, United States
• University of Southern California Keck Medical Center of USC — Los Angeles, California, United States
• UC Davis Medical Center — Sacramento, California, United States
• Children's Hospital Colorado — Aurora, Colorado, United States
• National Jewish Health Adult Cystic Fibrosis Center — Denver, Colorado, United States
• Children's National Medical Center — Washington D.C., District of Columbia, United States
• University of Florida Pediatrics — Gainesville, Florida, United States
• Memorial Healthcare System — Hollywood, Florida, United States
• Nemours Childrens Specialty Care — Jacksonville, Florida, United States
• University of Miami Bachelor Children's Hospital — Miami, Florida, United States
• Central Florida Pulmonary Group — Orlando, Florida, United States
• Arnold Palmer Hospital Pulmonary and Sleep Medical Institute Orlando Health, Inc — Orlando, Florida, United States
• Nemours Children's Hospital — Orlando, Florida, United States
• Nemours Children's Specialty Care — Pensacola, Florida, United States
• Johns Hopkins All Children's Hospital — St. Petersburg, Florida, United States
• Children's Health Care of Atlanta at Scottish Rite — Atlanta, Georgia, United States
• Augusta Univ Cystic Fibrosis Center — Augusta, Georgia, United States
• Chicago CF Care Specialists — Glenview, Illinois, United States
• NorthSurburban Pulmonary Specialists — Morton Grove, Illinois, United States
• Riley Hospital for Children at Indiana University Health — Indianapolis, Indiana, United States
• University of Iowa Department of Pediatrics — Iowa City, Iowa, United States
• Pulmonary Associates of Mobile — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.